Home › Non-Muscle Invasive Bladder Cancer › Pennsylvania
Non-Muscle Invasive Bladder Cancer clinical trials in Pennsylvania
9 studies for Non-Muscle Invasive Bladder Cancer are looking for participants at sites in Pennsylvania.
Cities in Pennsylvania
Testing the Addition of an Anti-Cancer Drug, Gemcitabine, to Usual Treatment (BCG Alone) in People Whose Non-Muscle Invasive Bladder Cancer (NMIBC) Came Back After Prior BCG Therapy
- Geisinger Medical Center, Danville
- Geisinger Cancer Center Dickson City, Dickson City
- Geisinger Medical Oncology-Lewisburg, Lewisburg
- and 3 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Oct 2, 2026 · NCT07000084A Clinical Study of Intismeran Autogene (V940) and BCG in People With Bladder Cancer (V940-011/INTerpath-011)
- MidLantic Urology ( Site 0102), Bala-Cynwyd
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Oct 1, 2026 · NCT06833073Efficacy and Safety of TYRA-300 in Participants With FGFR3 Altered Low Grade, Intermediate Risk Non-Muscle Invasive Bladder Cancer
- MidLantic Urology, Bala-Cynwyd
- Keystone Urology Specialists, Lancaster
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 29, 2026 · NCT06995677A Study to Evaluate TAR-210 Versus Intravesical Chemotherapy Treatment in Participants With High Risk Non-Muscle-Invasive Bladder Cancer
- MidLantic Urology, Bala-Cynwyd
- Keystone Urology Specialists, Lancaster
- University Of Pittsburgh Medical Center UPMC Hillman Cancer Center, Pittsburgh
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 28, 2026 · NCT06919965A Study to Assess Real-World Use and Outcomes of TAR-200 for Participants With Non-Muscle Invasive Bladder Cancer (NMIBC) in the United States
- MidLantic Urology - Haverford Road - Bryn Mawr, Bryn Mawr
RecruitingObservational study
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT07309445Safety and Efficacy Study of Intravesical Instillation of TARA-002 in Adults With High-grade Non-muscle Invasive Bladder Cancer
- University of Pittsburgh Medical Center, Pittsburgh
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Aug 24, 2026 · NCT05951179FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3
- Penn Medicine Lancaster General Hospital - Ann B. Barshinger Cancer Institute, Lancaster
- University of Pennsylvania, Philadelphia
- Thomas Jefferson University, Philadelphia
- and 2 more
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Aug 20, 2026 · NCT05614739LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve
- Thomas Jefferson University, Sidney Kimmel Cancer Center, Philadelphia
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Aug 7, 2026 · NCT04752722ResQ133A-NMIBC: Intravesical Recombinant Mycobacterium (rMBCG) in Participants With NMIBC Eligible to Receive Intravesical Tice BCG
- MidLantic Urology, Cynwyd
RecruitingPhase 1/2
Ages 18 to 85 · All sexes · Updated Mar 27, 2026 · NCT06800963From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.